Abstract
Background Diagnosis of toxoplasmic encephalitis (TE) is challenging under the best clinical circumstances. The poor sensitivity of quantitative polymerase chain reaction (qPCR) for Toxoplasma in blood and CSF and the limited availability of molecular diagnostics and imaging technology leaves clinicians in resource-limited settings with few options other than empiric treatment.
Methology/Principle Findings Here we describe proof of concept for a novel urine diagnostics for TE using Poly-N-isoproplyacrylamide nanoparticles dyed with Reactive Blue-221 to concentrate antigens, substantially increasing the limit of detection. After nanoparticle-concentration, a standard western blotting technique with a monoclonal antibody was used for antigen detection. Limit of detection was 7.8pg/ml and 31.3pg/ml of T. gondii antigens GRA1 and SAG1, respectively. To characterize this diagnostic approach, 164 hospitalized HIV-infected patients with neurological symptoms compatible with TE were tested for 1) T. gondii serology (121/147, positive samples/total samples tested), 2) qPCR in cerebrospinal fluid (11/41), 3) qPCR in blood (10/112), and 4) urinary GRA1 (30/164) and SAG1 (12/164). GRA1 appears to be superior to SAG1 for detection of TE antigens in urine. Fifty-one HIV-infected, T. gondii seropositive but asymptomatic persons all tested negative by nanoparticle western blot and blood qPCR, suggesting the test has good specificity for TE for both GRA1 and SAG1. In a subgroup of 44 patients, urine samples were assayed with mass spectrometry parallel-reaction-monitoring (PRM) for the presence of T. gondii antigens. PRM identified antigens in 8 samples, 6 of which were concordant with the urine diagnostic.
Conclusion/Significances Our results demonstrate nanoparticle technology’s potential for a noninvasive diagnostic test for TE. Moving forward, GRA1 is a promising target for antigen based diagnostics for TE.
Author Summary Toxoplasmic Encephalitis is a debilitating, yet highly treatable illness, classically seen in person living with HIV lacking treatment. Prompt diagnosis ensures the best outcome possible for patients, but remains a challenge: requiring invasive specimen collection, lacking necessary sensitivity, demanding significant technical skills and substantial infrastructure. Here we offer proof of concept of a diagnostic approach that is minimally invasive, using a urine-based approach that concentrates T. gondii antigens with hydrogel mesh nanoparticles to improve □sensitivity for detection by western blot. □
Competing Interest Statement
AL and LAL are inventors on patents US9 012 240 and US8 497 137 related to the affinity particles. Ceres Nanosciences licensed the rights of these patents that are owned by George Mason University. AL and LAL own shares of Ceres Nanosciences.
Funding Statement
HS: was supported by NIH Fogarty International Center Grant #D43TW009340
NMB: was supported by a NIAID K23 award (AI113197), UNC CFAR P30 AI50410, Fogarty R25TW009340, and Burroughs Wellcome Fund/ASTMH Postdoctoral Fellowship in Tropical Infectious Diseases.
CF and MD were supported by the Fogarty International Center of the National Institutes of Health under Award Number D43TW009343 and the University of California Global Health Institute.
RG: 1D43TW010074-01 supported the training of many of the Peruvian and Bolivian authors and working group members.
RG: NIAID R01 (AI136722-01) supported staff salaries and laboratory supplies in this investigation
LAL: supported staff salaries and laboratory supplies in this investigation with NICHD R21 (HD0974720).
AL: supported staff salaries and laboratory supplies in this investigation with NIAID R21 (AI138135)
The funders did not play any role in the study design, data collection and analysis, the decision to publish or the preparation of manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional review boards of study hospitals and involved institutions approved patient collection protocols. In Bolivia: In Bolivia: Universidad Catolica Boliviana - San Pablo, Santa Cruz; Hospital Clinico Viedma, Cochabamba; Instituto de Desarrollo Humano, Cochabamba; Colectivo de Estudios Aplicados, Desarrollo Social, Salud y Medio Ambiente, Cochabamba. In Peru: Hospital Regional de Loreto, Iquitos; Hospital Dos de Mayo, Lima; Asociacion Benefica Prisma, Lima; Universidad Peruana Cayetano Heredia, Lima. In the United States: University of North Carolina, Chapel Hill, NC and Johns Hopkins University, Baltimore, MD.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵& Members of the Toxoplasmosis working group in Peru and Bolivia can be found in the Acknowledgments
Funding: HS: was supported by NIH Fogarty International Center Grant #D43TW009340
NMB: was supported by a NIAID K23 award (AI113197), UNC CFAR P30 AI50410, Fogarty R25TW009340, and Burroughs Wellcome Fund/ASTMH Postdoctoral Fellowship in Tropical Infectious Diseases.
CF and MD were supported by the Fogarty International Center of the National Institutes of Health under Award Number D43TW009343 and the University of California Global Health Institute.
RG: 1D43TW010074-01 supported the training of many of the Peruvian and Bolivian authors and working group members.
RG: NIAID R01 (AI136722-01) supported staff salaries and laboratory supplies in this investigation
LAL: supported staff salaries and laboratory supplies in this investigation with NICHD R21 (HD0974720).
AL: supported staff salaries and laboratory supplies in this investigation with NIAID R21 (AI138135)
The funders did not play any role in the study design, data collection and analysis, the decision to publish or the preparation of manuscript.
Conflict of Interest: AL and LAL are inventors on patents US9,012,240 and US8,497,137 related to the affinity particles. Ceres Nanosciences licensed the rights of these patents that are owned by George Mason University. AL and LAL own shares of Ceres Nanosciences.
Prior Presentation of Findings Posters titled “Diagnosis of Neurological Toxoplasmosis in Urine in Persons Living with HIV,” October 2019; “Diagnosis of Toxoplasmic Encephalitis in Person Living with HIV in Urine,” November 2018; and “Diagnosis of Toxoplasmosis Reactivation in HIV Patients in Urine Using Nanoparticle Technology, November 2016” were present at the annual meetings of the American Society for Tropical Medicine and Hygiene.
Data Availability
Data is available in the manuscript and supporting figures. Any additional data may be requested of the corresponding author.
